The ANTIDOTE Institute

Quick Info

Application Deadline:
January 7, 2023

Participant Notification:
February 15, 2023

First Group Meeting:
At ACMT ASM in March 2023

Send Applications To:
antidote.admin@acmt.net

Questions about the program? Reach out to the program leadership anytime! We would be happy to have a call/zoom to discuss the program in more detail and help determine if it is a good fit for your career goals.

Advancing New Toxicology Investigators in Drug Abuse and Original Translational Research Efforts
Sponsored by ACMT, The ToxInnovation Lab (UMASS), and The Chai Lab (Harvard Medical School)

Medical toxicologists play an important role in defining the care of poisoned patients. Outside of providing clinical care, toxicologists have advanced the science around antidotal therapy, management of the poisoned patient, occupational exposures, and substance use disorder. The discovery and development of the next practice driving advancements in toxicology require rigorous research, and a pipeline of new investigators to drive the field forward. In order to support a career in research, toxicologists need knowledge and skills related to identifying and securing funding sources, scientific writing for knowledge dissemination, and ethical research conduct. Additionally, prospective investigators need to identify a strong network of mentors and collaborators to help them grow their own research program. The ANTIDOTE Institute provides an opportunity for fellows and junior faculty to begin to develop their own area of investigation, network with peers and experienced investigators in the field, and gather practical knowledge on topics core to developing a successful research program.

The Opportunity

One year long course consisting of 1) focused, small group sessions with moderated peer review, mentorship and discussion of core topics surrounding research fundamentals and 2) one-on-one mentorship from an established investigator in medical toxicology.

The program is intended to help you develop and implement a feasible research project that will serve as a foundation for your career as an investigator. Of note, this is not formal didactic course on research methodology. We have designed the curriculum to give you basic skills around thinking about research, developing a grant, setting up a budget, writing manuscripts and setting up infrastructure for success. As part of the course, we also have paired each of you up with an ACMT researcher outside your institution. We hope this relationship will be valuable to you as you can learn from their experiences, and they can provide you feedback on your research and goals.

Eligibility

Applicants must be toxicology fellows or junior faculty (within 3 years of fellowship graduation) for the 2022-2023 academic year. 

Application Process

Interested applicants will need to provide:

  • A cover letter which includes a brief statement of interest and description of research interests/experience (1 page maximum)
    • Note: Research interests do not need to be well-developed at this stage; a basic description of interest is appropriate. The expectation is that the participants will be mentored during the initiative to develop their research ideas.
  • CV
  • Letter of commitment from Med Tox program director confirming the applicant will have the availability and protected time to fully participate in all sessions (for fellow applicants only)

Commitment

  • Participation in virtual small group sessions (approximately 2 hours) every other month. These sessions will consist of group discussion around core research concepts as well as group discussion around individual institute member research projects
  • Participation in 30-minute monthly meetings with your mentors to update on your progress during the ANTIDOTE institute and for career advice
  • Attendance at two in person ANTIDOTE retreats at ACMT’s Annual Scientific Meeting (ASM 2023 and ASM 2024).  We will also have a more informal meet up at NACCT, but this is optional to attend

Please submit all application packets to antidote.admin@acmt.net by January 7, 2023.  Selected participants will be notified via email by February 15, 2023. The first group meeting will be held at ACMT ASM in March 2023.

Program Administrators

Stephanie Carreiro, MD

Program Chair
stephanie.carreiro@umassmed.edu

Read Bio

Stephanie Carreiro, MD, is an emergency medicine physician and medical toxicologist. She is a 2009 graduate of New York Medical College and completed her Emergency Medicine Residency in 2013 at Brown University. She completed a medical toxicology fellowship at the University of Massachusetts in 2015 and remained on faculty as an Assistant Professor of Emergency Medicine. Dr. Carreiro has a passion for novel translational research, which she first discovered during residency while evaluating novel antidotes for cardiotoxicity in animal models. She now focuses on clinical research in substance use disorder space, with a particular focus on the current opioid epidemic. Her current research interests include the utilization of novel technologies and serum biomarkers to evaluate drug toxicity, substance abuse, and addiction. Dr. Carreiro is also currently pursuing a PhD in Biomedical Sciences from the University of Massachusetts Medical School.

Peter R Chai, MD, MMS

Program Co-Chair
pchai@bwh.harvard.edu

Read Bio

Dr. Peter R Chai is an assistant professor of emergency medicine and medical toxicology at Brigham and Women’s Hospital/Harvard Medical School, an affiliate research scholar at the Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology, and The Fenway Institute. He is also research faculty at the Dana Farber Cancer Institute. Dr. Chai’s career focuses on the development and implementation of technological solutions that detect and respond to changes in disease. His arc of translational science ranges from the design of novel robotic and sensor systems in animal models to human clinical trials to test the implementation of injectable and ingestible sensor systems and overlying behavioral science architecture to respond to disease states. Dr. Chai is principal investigator on grants from the National Institutes of Health, and other foundation and industry sources to develop a range of electronic devices ranging from ingestible electronic sensors that measure medication adherence, music that alters the experience of pain, robotic systems to understand population exposures to pharmaceuticals and infectious diseases and robotic systems to facilitate contactless care of patients in the emergency department.

Alison Meyn, MPH

Program Administrator
alison.meyn@acmt.net

Read Bio

Alison is a Clinical Research Quality Analyst with ACMT. Alison received her MPH in Epidemiology from the School of Public Health at Georgia State University. She has been an epidemiologist for three years working in infectious disease and chronic disease with experience in case investigation, disease surveillance, database creation, data analytics, and more recently was a COVID-19 first responder. She has contributed to a number of public health projects in the fields of: Maternal and Child Health, Cancer, HIV, Oral Health, Smoking Cessation, and COVID-19.

Alison has worked in clinical research as well, working with private pharmaceuticals in Phase I and Phase II oncology clinical trials throughout the U.S. and Europe. Originally from Savannah, Georgia she now resides in Cape Coral, FL with her family and dogs.

ANTIDOTE Classes by Year

Caitlin Bonney, MD

Caitlin Bonney, MD is a medical toxicologist and emergency physician. She is board eligible in medical toxicology and board-certified in emergency medicine. Her current duties include service at the Northern New England Poison Center including the development of policies and protocols for the Northern New England region, supervising poison specialists, and teaching medical students, residents, and pharmacy students. She also maintains an adjunct faculty position at the University of Nevada Las Vegas where she is involved in teaching residents, advising pharmacy protocols, and serving on the medical school Curriculum Oversight Committee. In her clinical duties, she works as an attending emergency physician at Maine Medical Center and Exeter Hospital. She serves on national committees related to toxicology including the American College of Emergency Physicians Excited Delirium Task Force. She conducts ongoing research on opioid use disorder.

Marielle Brenner, MD

Marielle Brenner, MD is an emergency medicine physician and medical toxicologist. She trained in emergency medicine at the Medical College of Wisconsin in Milwaukee, WI and trained in medical toxicology at Indiana University in Indianapolis, IN. After fellowship, she joined the faculty at the University of Iowa in Iowa City, IA as an Assistant Professor in Emergency Medicine and Medical Toxicology. Her academic interests include the toxicology of combined opioid and sympathomimetic toxicity including the biochemical pathways of the underlying addiction of combined ingestion. Research goals include developing a better understanding of the neuroplasticity that occurs with opioid and stimulant addiction to allow for better pharmacotherapies for this patient population.

Eric Kaczor, MD

Eric Kaczor, MD, is a board-certified emergency medicine physician and board-eligible medical toxicologist. He earned his medical degree at the University at Buffalo, Jacobs School of Medicine and Biomedical Sciences in 2016, and completed his Residency in Emergency Medicine and Fellowship in Medical Toxicology at the University of Massachusetts Medical Center in 2019 and 2021 respectively. After graduation, he took a position at the University of Pittsburgh Medical Center and will be starting a volunteer faculty position in the upcoming academic year. His research interests include characterizing the potential adverse effects of cannabis product exposures, exploring the content and labeling strategies of commercially available cannabis products, and the use of biosensors as a means of detecting intoxication/impairment.

David Liss, MD

David Liss, MD is a faculty member at Washington University in St. Louis in the Department of Emergency Medicine, Division of Medical Toxicology. He graduated fellowship in 2017 and has been practicing Medical Toxicology for 5 years. His interest in the ANTIDOTE Institute program comes from his recent academic focus in medical toxicology and addiction medicine research. He has completed two retrospective observational studies of patients treated by the medical toxicology consult service with opioid use disorder and the rates of follow-up with a local care coordination program. In addition, he is in the final stage of data collection and analysis for a Medical Toxicology Foundation grant studying mass spectrometry for universal urine drug screening in pregnancy compared with standard of care screening. He has several thoughts on the next steps, and hopes that participating in this program would give him a sounding board for focusing his research efforts as well as help him to improve the quality of his future projects.

Michael Simpson, MD

Michael Simpson, MD, is a first-year medical toxicology fellow at the Harvard Medical Toxicology Program at Boston Children’s Hospital and the Massachusetts and Rhode Island Poison Control Center. He attended medical school at the University of Central Florida in his hometown of Orlando, Florida, and then completed residency training in emergency medicine at Vanderbilt University. His research interests include practice variations in the care of poisoned patients.

James Whitledge, MD

Jim Whitledge is currently a medical toxicology fellow at Boston Children’s Hospital, and also works as an emergency medicine physician at Beth Israel Deaconess Medical Center and Winchester Hospital in the Boston area. He attended Tufts University School of Medicine and subsequently completed emergency medicine residency at Beth Israel Deaconess Medical Center, where he served as chief resident. His current research interests include ED-based treatment for alcohol use disorder, cannabis and the impact of its legalization, and drug shortage solutions.

Brandtly Yakey, DO

Brandtly Yakey is a first-year medical toxicology fellow at Wayne State University Michigan Poison and Drug Information Center, as well as an emergency physician at Detroit Medical Center in Detroit, Michigan. He completed residency training at Michigan State University/Sparrow in Lansing, Michigan. Toxicology interests include therapeutics and addiction/withdrawal.

Kevin Baumgartner, MD

Kevin Baumgartner, MD, is an emergency medicine physician and medical toxicologist. He trained in Emergency Medicine and Medical Toxicology at Washington University School of Medicine and now joins the Division of Medical Toxicology as an Assistant Professor. He is the co-director of the Introduction to Addiction Medicine medical student elective and a member of the editorial board of Clinical Toxicology. Dr. Baumgartner’s research and clinical interests include addiction medicine, quality improvement, psychopharmacology, and snake envenomation.

Mary Billington, MD

Dr. Mary Billington is a board-certified medical toxicologist and emergency medicine physician. She completed both Emergency Medicine Residency and Medical Toxicology Fellowship at Parkland Hospital. She currently holds the academic position of Assistant Professor of Emergency Medicine at the University of Texas Health and Science Center in Houston, TX. The application of mathematical modeling and analysis to the field of toxicology is her primary research interest.

Joseph Carpenter, MD

Joseph Carpenter, MD is an Assistant Professor in the Medical Toxicology Section, Department of Emergency Medicine at the Emory University School of Medicine. He is a graduate of Brown University and the Stanford University School of Medicine. Dr. Carpenter completed his residency in emergency medicine at Los Angeles County Harbor-UCLA Medical Center and fellowship in medical toxicology at Emory University and the Centers of Disease Control and Prevention. His clinical time is split between Grady Memorial Hospital’s emergency department, medically assisted opioid treatment clinic, and medical toxicology consultation service, as well as the Georgia Poison Center. His research interests lie at the growing intersection of emergency medicine, medical toxicology, and addiction medicine.

Aaron S. Frey, DO

Dr. Aaron Frey was born and raised in Forest, Virginia. He moved to North Carolina to attend Campbell University for his undergraduate education where he double majored in Spanish and government with a concentration in international studies and minored in history. While in North Carolina, he became a firefighter and emergency medicine technician. His first responder experiences made him want to pursue a career in medicine. He obtained the prerequisite medical school courses from Campbell University and became a student researcher in the cellular biology department. He attended the Via College of Osteopathic Medicine in Blacksburg, Virginia where he continued to work as a student researcher. There, he studied the protective effects of cerium oxide nanoparticles in traumatic brain injury and Parkinson’s Disease. He completed an emergency medicine residency at the Lehigh Valley Health Network in Allentown, Pennsylvania in 2019. He worked in a small, resource-limited hospital in northeast Pennsylvania during the COVID-19 pandemic and treated many critically ill patients. He then decided to pursue additional training in medical toxicology and is currently a medical toxicology fellow at the University of Virginia.

Marc Rigatti, MD, PhD

Marc Rigatti MD, PhD is currently a senior medical toxicology fellow at UMass Medical School. He began his education at Eastern Connecticut State University and graduated with degrees in biochemistry and biology. He then moved on to University of Connecticut, where he earned a Master’s in biochemistry while studying the chemotherapeutic potential of mdm2 inhibitors in colorectal cancer. Dr. Rigatti completed his MD/PhD at the UConn School of medicine in 2017. He earned his PhD in cell analysis and modeling by studying the biophysical mechanisms that allow A Kinase Anchoring Proteins coordinate PKA signaling microdomains, thereby regulating phosphorylation of specific PKA substrates. Dr. Rigatti completed a residency in emergency medicine at the UConn Emergency Medicine Program in Hartford, CT, where he also served as chief resident. His current research interests focus on the use of wearable biosensors and machine learning to measure pain severity and to detect states of intoxication.

Christopher Watson, MD

Dr. Watson is a second-year medical toxicology fellow with the Harvard Medical Toxicology Program at Boston Children’s Hospital and the Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island, as well as an emergency medicine physician at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. A native of Portland, Maine, Dr. Watson completed medical school at The University of Chicago Pritzker School of Medicine and residency training at the BIDMC Harvard Affiliated Emergency Medicine Residency. He has strong clinical and academic interests in resource utilization with regard to toxicologic emergencies.